Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
West Virginia University
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Body mass index (BMI) greater than 30 kg/m2, who are eligible for ESG
Patients scheduled to undergo an endoscopic bariatric weight loss procedure (ESG)
Patients older than 18 years and younger than 75 years of age at the time of consent
Patients able to provide written informed consent on the Institutional review board (IRB) approved informed consent form
Patients willing and able to comply with study requirements for follow-up
You may not be if
Patients who are treated with intragastric balloons
Family history of esophageal, gastric, or duodenal malignancy and active gastric ulceration,
Pre-existing esophageal stenosis/stricture preventing the advancement of an endoscope during screening/baseline Esophagogastroduodenoscopy (EGD)
Presence of any gastric condition which required endoscopic surveillance (e.g., known gastric intestinal metaplasia),
Known vascular abnormalities, obligate therapeutic anticoagulation, and pregnancy/lactation
Evidence of end-stage liver disease, including portal hypertension, ascites, and coagulopathy
Positivity for hepatitis B virus or hepatitis C virus, current alcohol consumption of more than 20 g/day in females and more than 30 g/day in males on average, use of medications with reported hepato-steatogenic effect (amiodarone, tamoxifen, estrogens), and drug-induced liver disease
Known positivity for human immunodeficiency virus, a concomitant disease with reduced life expectancy, severe psychiatric condition, drug dependence, or inability to provide informed consent.
The patient refuses or is unable to provide written informed consent